Table 1.
Baseline demographic characteristics in phase 1
| 5 μg group (n=20) | 10 μg group (n=20) | 15 μg group (n=20) | 20 μg group (n=20) | 25 μg group (n=20) | Placebo group*(n=20) | Total(n=120) | ||
|---|---|---|---|---|---|---|---|---|
| Sex | ||||||||
| Male | 15 (75%) | 12 (60%) | 14 (70%) | 8 (40%) | 11 (55%) | 15 (75%) | 75 (62.5) | |
| Female | 5 (25%) | 8 (40%) | 6 (30%) | 12 (60%) | 9 (45%) | 5 (25%) | 45 (37.5) | |
| Age, years | 30·5 (23·3–38·0) | 28·0 (24·3–38·8) | 24·0 (21·0–29·3) | 27·0 (22·3–39·0) | 26·5 (22·3–29·8) | 25·0 (22·0–30·0) | 27·0 (22·0–34·8) | |
| Ethnicity | ||||||||
| Han | 20 (100%) | 20 (100%) | 19 (95%) | 20 (100%) | 19 (95%) | 20 (100%) | 118 (98%) | |
| Others | 0 | 0 | 1 (5%) | 0 | 1 (5%) | 0 | 2 (2%) | |
| Body-mass index, kg/m2 | 24·3 (3·2) | 24·1 (3·1) | 24·8 (3·5) | 23·4 (2·8) | 23·7 (3·6) | 23·6 (2·8) | 24·2 (3·1) | |
| Medical history or existing disorder | ||||||||
| Hypertension | 1 (5) | 0 | 0 | 0 | 0 | 0 | 0 | |
Data are n (%), mean (SD), or median (IQR).
*
Participant data taken from all five blocks.